Kintara Therapeutics, Inc. (KTRA)
NASDAQ: KTRA · Real-Time Price · USD
0.187
-0.002 (-1.27%)
Aug 30, 2024, 4:00 PM EDT - Market closed
Kintara Therapeutics Employees
Kintara Therapeutics had 2 employees as of June 30, 2023. The number of employees decreased by 1 or -33.33% compared to the previous year.
Employees
2
Change (1Y)
-1
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,756,000
Market Cap
10.33M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CareMax | 1,450 |
XWELL | 337 |
Ontrak | 104 |
Molecular Templates | 62 |
RedHill Biopharma | 53 |
Jaguar Health | 49 |
Kiora Pharmaceuticals | 12 |
Inhibikase Therapeutics | 9 |
KTRA News
- 12 days ago - TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer - PRNewsWire
- 7 weeks ago - TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor - PRNewsWire
- 2 months ago - Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones - PRNewsWire
- 3 months ago - TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) - PRNewsWire
- 3 months ago - Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results - PRNewsWire
- 5 months ago - KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA - Business Wire
- 5 months ago - Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement - PRNewsWire
- 5 months ago - Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab - PRNewsWire